Preclinical development of an EP2 antagonist for post-seizure cognitive deficits. (15th February 2023)

• Record Type: Journal Article
• Authors: Varvel, Nicholas H.; Amaradhi, Radhika; Espinosa-Garcia, Claudia; Duddy, Steven; Franklin, Ronald; Banik, Avijit; Alemán-Ruiz, Carlos; Blackmar-Raynolds, Lisa; Wang, Wenyi; Honore, Tage; Ganesh, Thota; Dingledine, Raymond
• Is Part Of: Neuropharmacology. Volume 224(2023)
• Publication Date: 2023-02-15
• Subjects: Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2022.109356
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: Cognitive comorbidities can substantially reduce quality of life in people with epilepsy. Inflammation is a component of all chronic diseases including epilepsy, as well as acute events like status epilepticus (SE). Neuroinflammation is the consequence of several broad signaling cascades including cyclooxygenase-2 (COX-2)-associated pathways. Activation of the EP2 receptor for prostaglandin E2 appears responsible for blood-brain barrier leakage and much of the inflammatory reaction, neuronal injury and cognitive deficit that follows seizure-provoked COX-2 induction in brain. Here we show that brief exposure of mice to TG11-77, a potent, selective, orally available and brain permeant EP2 antagonist, eliminates the profound cognitive deficit in Y-maze performance after SE and reduces delayed mortality and microgliosis, with a minimum effective i.p. dose (as free base) of 8.8 mg/kg. All in vitro studies required to submit an investigational new drug (IND) application for TG11-77 have been completed, and non-GLP dose range-finding toxicology in the rat identified no overt, organ or histopathology signs of toxicity after 7 days of oral administration at 1000 mg/kg/day. Plasma exposure in the rat was dose-linear between 15 and 1000 mg/kg dosing. TG11-77 thus appears poised to continue development towards the initial clinical test of the hypothesis that EP2 receptor modulation after SE can provide the first preventive treatment for one of the chief comorbidities of epilepsy. Highlights: Preventing cognitive deficits after status epilepticus and in epilepsy is a major goal in the epilepsy community. Antagonists of the EP2 receptor quench neuroinflammation caused by cyclooxygenases but avoid toxicities of COX-2 inhibitors. We demonstrate that blocking EP2 receptors reduces delayed mortality after status epilepticus and rescues a memory deficit. We present a strong foundation of preclinical data that supports progression of TG11-77 to the clinic.